Stock & Company Details
InflaRx N.V. $IFRX
Price:
46,691,331
72M
$330M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
0.00
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
IFRX technical indicators
Latest InflaRx N.V. (IFRX) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
63.73 4.4%
MACD:
0.03 485.0%
SMA 50:
$2.09 0.6%
SMA 200:
$1.36 0.4%
EMA 20:
$2.01 1.7%
Bollinger Bands:
2.31 / 1.43
Stochastic:
67.58 3.5%
ADX 14:
25.56 6.9%
ATR 14:
0.22 3.5%
CCI 20:
170.08 11.4%
OBV:
205.47M 0.9%
ROC 12:
45.63% 36.9%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Finance Bot
Ask your questions
Start by typing a question below.
